Optiver Holding B.V. Decreases Holdings in argenex SE $ARGX

Optiver Holding B.V. lowered its holdings in argenex SE (NASDAQ:ARGX) by 34.9% during the third quarter, HoldingsChannel reports. The fund owned 11,328 shares of the company’s stock after selling 6,066 shares during the period. Optiver Holding B.V.’s holdings in argenex were worth $8,355,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ARGX. Bessemer Group Inc. lifted its stake in argenex by 276.5% during the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after purchasing an additional 47 shares during the last quarter. MAI Capital Management raised its holdings in argenex by 866.7% during the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after purchasing an additional 78 shares in the last quarter. Mather Group LLC. purchased a new stake in shares of argenex during the 3rd quarter worth approximately $50,000. Rossby Financial LCC lifted its position in shares of argenex by 115.2% during the 3rd quarter. Rossby Financial LCC now owns 71 shares of the company’s stock worth $54,000 after buying an additional 38 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its holdings in shares of argenex by 750.0% in the 3rd quarter. TD Private Client Wealth LLC now owns 85 shares of the company’s stock valued at $63,000 after buying an additional 75 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Citigroup dropped their target price on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Morgan Stanley raised their price objective on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. TD Cowen upped their target price on argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, Wolfe Research restated a “peer perform” rating on shares of argenex in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus price target of $986.78.

argenex Stock Up 1.7%

NASDAQ ARGX opened at $840.28 on Wednesday. The firm has a 50-day moving average price of $830.51 and a 200 day moving average price of $810.08. The stock has a market capitalization of $52.00 billion, a P/E ratio of 36.08, a P/E/G ratio of 0.71 and a beta of 0.37. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.